Xueqiu Jian

Xueqiu Jian

Auto-generated profile, based on publicly available information

Xueqiu Jian

Glenn Biggs Institute for Alzheimer’s and Neurodegenerative Diseases, San Antonio, USA

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
4 April 2022 in Nature Genetics
Verified
Journal Article
Open access
PDF file
CBCéline Bellenguez
Céline Bellenguez
FKFahri Küçükali
Fahri Küçükali
IJIris E. Jansen
Iris E. Jansen
LKLuca Kleineidam
Luca Kleineidam
SMSonia Moreno-Grau
Sonia Moreno-Grau
JLJean-Charles Lambert
Jean-Charles Lambert
Characterization of the genetic landscape of Alzheimer’s disease (AD) and related dementias (ADD) provides a unique opportunity for a better understanding of the associated pathophysiological processes. We performed a two-stage genome-wide association study totaling 111,326 clinically diagnosed/‘proxy’ AD cases and 677,663 controls. We found 75 risk loci, of which 42 were new at the time of analysis. Pathway enrichment analyses confirmed the involvement of amyloid/tau pathways and highlighted microglia implication. Gene prioritization in the new loci identified 31 genes that were suggestive of new genetically associated processes, including the tumor necrosis factor alpha pathway through the linear ubiquitin chain assembly complex. We also built a new genetic risk score associated with the risk of future AD/dementia or progression from mild cognitive impairment to AD/dementia. The improvement in prediction led to a 1.6- to 1.9-fold increase in AD risk from the lowest to the highest decile, in addition to effects of age and the APOE ε4 allele.

7 June 2021 in Nature Communications
Verified
Journal Article
Open access
PDF file
IRItziar de Rojas
Itziar de Rojas
SMSonia Moreno-Grau
Sonia Moreno-Grau
NTNiccolo Tesi
Niccolo Tesi
BGBenjamin Grenier-Boley
Benjamin Grenier-Boley
VAVictor Andrade
Victor Andrade
ARAgustín Ruiz
Agustín Ruiz
Genetic discoveries of Alzheimer’s disease are the drivers of our understanding, and together with polygenetic risk stratification can contribute towards planning of feasible and efficient preventive and curative clinical trials. We first perform a large genetic association study by merging all available case-control datasets and by-proxy study results (discovery n = 409,435 and validation size n = 58,190). Here, we add six variants associated with Alzheimer’s disease risk (near APP, CHRNE, PRKD3/NDUFAF7, PLCG2 and two exonic variants in the SHARPIN gene). Assessment of the polygenic risk score and stratifying by APOE reveal a 4 to 5.5 years difference in median age at onset of Alzheimer’s disease patients in APOE ɛ4 carriers. Because of this study, the underlying mechanisms of APP can be studied to refine the amyloid cascade and the polygenic risk score provides a tool to select individuals at high risk of Alzheimer’s disease.

8 December 2020 in Nature Communications
Verified
Journal Article
Open access
PDF file
MSMuralidharan Sargurupremraj
Muralidharan Sargurupremraj
HSHideaki Suzuki
Hideaki Suzuki
XJXueqiu Jian
Xueqiu Jian
CSChloe Sarnowski
Chloe Sarnowski
TETavia E. Evans
Tavia E. Evans
SDStéphanie Debette
Stéphanie Debette
White matter hyperintensities (WMH) are the most common brain-imaging feature of cerebral small vessel disease (SVD), hypertension being the main known risk factor. Here, we identify 27 genome-wide loci for WMH-volume in a cohort of 50,970 older individuals, accounting for modification/confounding by hypertension. Aggregated WMH risk variants were associated with altered white matter integrity (p = 2.5×10-7) in brain images from 1,738 young healthy adults, providing insight into the lifetime impact of SVD genetic risk. Mendelian randomization suggested causal association of increasing WMH-volume with stroke, Alzheimer-type dementia, and of increasing blood pressure (BP) with larger WMH-volume, notably also in persons without clinical hypertension. Transcriptome-wide colocalization analyses showed association of WMH-volume with expression of 39 genes, of which four encode known drug targets. Finally, we provide insight into BP-independent biological pathways underlying SVD and suggest potential for genetic stratification of high-risk individuals and for genetically-informed prioritization of drug targets for prevention trials.

12 April 2021 in Aging
Verified
Journal Article
Open access
LMLaura Madrid
Laura Madrid
A(Alzheimer’s Disease Neuroimaging Initiative (Adni)
Alzheimer’s Disease Neuroimaging Initiative (Adni)
ACADAPTED consortium
ADAPTED consortium
SMSonia Moreno-Grau
Sonia Moreno-Grau
SAShahzad Ahmad
Shahzad Ahmad
MSMaria E Saez
Maria E Saez
Alzheimer's disease (AD) is the most common form of dementia, currently affecting 35 million people worldwide. Apolipoprotein E (APOE) ε4 allele is the major risk factor for sporadic, late-onset AD (LOAD), which comprises over 95% of AD cases, increasing the risk of AD 4-12 fold. Despite this, the role of APOE in AD pathogenesis is still a mystery. Aiming for a better understanding of APOE-specific effects, the ADAPTED consortium analysed and integrated publicly available data of multiple OMICS technologies from both plasma and brain stratified by APOE haplotype (APOE2, APOE3 and APOE4). Combining genome-wide association studies (GWAS) with differential mRNA and protein expression analyses and single-nuclei transcriptomics, we identified genes and pathways contributing to AD in both APOE dependent and independent fashion. Interestingly, we characterised a set of biomarkers showing plasma and brain consistent protein profiles and opposite trends in APOE2 and APOE4 AD cases that could constitute screening tools for a disease that lacks specific blood biomarkers. Beside the identification of APOE-specific signatures, our findings advocate that this novel approach, based on the concordance across OMIC layers and tissues, is an effective strategy for overcoming the limitations of often underpowered single-OMICS studies.

22 July 2020 in Translational Psychiatry
Verified
Journal Article
Open access
PDF file
XJXueqiu Jian
Xueqiu Jian
TSTamar Sofer
Tamar Sofer
WTWassim Tarraf
Wassim Tarraf
JBJan Bressler
Jan Bressler
JFJessica D. Faul
Jessica D. Faul
MFMyriam Fornage
Myriam Fornage
Cognitive function such as reasoning, attention, memory, and language is strongly correlated with brain aging. Compared to non-Hispanic whites, Hispanics/Latinos have a higher risk of cognitive impairment and dementia. The genetic determinants of cognitive function have not been widely explored in this diverse and admixed population. We conducted a genome-wide association analysis of cognitive function in up to 7600 middle aged and older Hispanics/Latinos (mean = 55 years) from the Hispanic Community Health Study / Study of Latinos (HCHS/SOL). Four cognitive measures were examined: the Brief Spanish English Verbal Learning Test (B-SEVLT), the Word Fluency Test (WFT), the Digit Symbol Substitution Test (DSST), the Six-Item Screener (SIS). Four novel loci were identified: one for B-SEVLT at 4p14, two for WFT at 3p14.1 and 6p21.32, and one for DSST at 10p13. These loci implicate genes highly expressed in brain and previously connected to neurological diseases (UBE2K,FRMD4B, theHLAgene complex). By applying tissue-specific gene expression prediction models to our genotype data, additional genes highly expressed in brain showed suggestive associations with cognitive measures possibly indicating novel biological mechanisms, includingIFT122in the hippocampus for SIS,SNX31in the basal ganglia for B-SEVLT,RPS6KB2in the frontal cortex for WFT, andCSPG5in the hypothalamus for DSST. These findings provide new information about the genetic determinants of cognitive function in this unique population. In addition, we derived a measure of general cognitive function based on these cognitive tests and generated genome-wide association summary results, providing a resource to the research community for comparison, replication, and meta-analysis in future genetic studies in Hispanics/Latinos.

24 September 2025 in Communications Biology
Verified
Journal Article
Open access
PDF file
CSChloe Sarnowski
Chloe Sarnowski
YZYixin Zhang
Yixin Zhang
FAFarah Ammous
Farah Ammous
LSLincoln M. P. Shade
Lincoln M. P. Shade
DDDaniel DiCorpo
Daniel DiCorpo
AMAlanna Morrison
Alanna Morrison
To better characterize the potential biological mechanisms underlying insulin resistance (IR) and dementia, we derive cross-population and population specific polygenic scores [PSs] for fasting insulin and IR-related partitioned PSs [pPSs]. We conduct a cross-sectional study of the associations of these genetic scores with neurological outcomes in >17k participants (36% men, mean age 55 yrs) from the Trans-Omics for Precision Medicine (TOPMed) program (50% Non-Hispanic White, 23% Black/African American, 21% Hispanic/Latino American, and 4% Asian American). We report significant negative associations (P < 0.002) of the cross-population (P = 1.3 × 10-5) and European (PEA = 3.0 × 10-8) fasting insulin PSs with total cranial volume, and of a metabolic syndrome European PS with general cognitive function (BEA = -0.13, PEA = 0.0002) and lateral ventricular volume (BEA = 0.09, PEA = 0.002). We identify suggestive negative associations (P < 0.007) of metabolic syndrome and obesity pPSs with general cognitive function, and of lipodystrophy pPSs with total cranial volume. A higher genetic predisposition to IR is associated with lower brain size, and a genetic predisposition to specific IR-related type 2 diabetes subtypes, such as metabolic syndrome and mechanisms of IR mediated through obesity and lipodystrophy, is potentially involved in cognitive decline.